Table 1 Final priorities in Big Data and ICT solutions and Bringing innovation to the market
Topic | Priority | |
|---|---|---|
Big Data and ICT solutions | 1 | Select Big Data and make them analysable, comparable, and interoperable across borders |
2 | Consider data security measures when developing new ICT solutions | |
3 | Enforce the implementation and usage of data standards in Personalised Medicine | |
4 | Adopt ICT solutions to health challenges globally, not just focusing on high-income countries | |
5 | Foster global efforts and joint policies for creating safe zones for cross-border data sharing | |
6 | Stimulate cooperation between academia and industry, facilitating data exchange procedures | |
7 | Embrace the societal and cultural differences among countries with the aim of safeguarding public trust in government and state authorities | |
Bringing innovation to the market | 1 | Ensure PM stakeholders follow shared principles and universal data sharing and exchange guidelines when using advanced diagnostics |
2 | Focus newly marketed solutions on maximising patient health outcomes | |
3 | Assure that health insurance providers extend their coverage to innovative PM solutions and that the reimbursement of services is guaranteed | |
4 | Reduce the economic costs and lower the barriers to the market uptake of personalised diagnostics | |
5 | Intensify the dialogue between public health systems and the developers of PM solutions and products | |
6 | Urge stakeholders to have a holistic and long-term perspective on the budget when placing priorities on innovation | |
7 | Elaborate on cost-effectiveness and economic analysis models that consider the social and healthcare budgets | |
8 | Extend the role of personalised diagnostics in sustainable medical treatment | |
9 | There is a greater need for early, intense, coordinated, and continued crosstalk among all PM stakeholders to support breakthrough innovations | |
10 | Reward innovations that aim for a higher therapeutic value and guide innovation efforts towards the most relevant areas | |
11 | Develop methodologies to measure the social value of pharmaceutical products and systematically use such methods, e.g., in the context of health technology assessment | |
12 | Keep into account the interconnection and mutual dependency between diagnostics and therapeutics | |